BC-005 is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BC-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BC-005 overview

BC-005 is under development for the treatment of asthma, atopic dermatitis. The drug candidate is a monoclonal antibody that acts by targeting interleukin 4 receptor (IL-4R).

Dragonboat Biopharmaceutical (Shanghai) overview

Dragonboat Biopharmaceutical (Shanghai) (Dragonboat Biopharmaceutical), a subsidiary of Guilin Sanjin Pharmaceutical Co Ltd, is a biopharmaceutical company that researches and develops biologics for cancers and autoimmune diseases. The company pipeline product includes BC003, BC001, BC005, BC006, BC007, BC008, BC010, BC011 and BCT2101. Dragonboat Biopharmaceutical drug candidate targets include solid tumors, tenosynovial giant cell tumors, asthma, gastric cancer and pancreatic cancer among others. It also utilizes an In-house systemic platform. The company operates a drug research and development center that covers early discovery, preclinical research, IND, clinical research, biologics license application and manufacturing. Dragonboat Biopharmaceutical is headquartered in Shanghai, China.

For a complete picture of BC-005’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.